Micreos

Micreos is a platform biotech company focused on discovering and developing recombinant proteins for chronic dermatological disease Micreos is a clinical-stage pharmaceutical biotech developing medicinal solutions that selectively kill only harmful bacteria while preserving the rest of the health-enhancing microbiome. Our vision is to positively impact patient care while helping global health care systems to address impending anti-microbial resistance (AMR) concerns. Our unique capability in modular engineering to optimize enzyme therapeutics means that we have already developed three endolysin-based investigational antimicrobials. These antimicrobials are focused on the detrimental impact of Staphylococcus aureus (S. aureus) in oncology, dermatology and bloodstream infections. Our team is forging ahead, partnering across medicine, to realize the shared goal of better solutions to combat harmful bacteria in an era of antimicrobial resistance. Welcome to Micreos. Beyond resistance